Sienna Announces Research Collaboration with Princess Alexandra Hospital and Pathology Queensland

28-Oct-2015

In an expansion of their global network of scientific and clinical research partners, Sienna Cancer Diagnostics has entered a research collaboration with the Princess Alexandra Hospital and Pathology Queensland to broaden utility of telomerase detection in specimens being investigated for cancer.

The study, led by Dr Kasturi Vaska (Cytopathologist) and Sandra Wood (Scientist), will investigate the use of Sienna’s telomerase detection technology as an adjunct test in fluid samples, including but not limited to pancreatic, lung, thyroid and pleural fluids collected for routine cytological examination for cancer diagnosis. The outcomes of this research will help guide the expanded utility of Sienna’s in-vitro diagnostic (IVD) for the detection of telomerase in a range of cytological sample types.

Sienna’s CEO, Dr Cliff Holloway said “Sienna will be the first company to provide an IVD product to the market for the detection of telomerase which is recognised as an important biomarker in over 90% of cancers. Working with dedicated clinical research partners such as Princess Alexandra Hospital and Pathology Queensland is invaluable to ensuring that Sienna’s products are robust, validated, effective, and can be easily integrated into existing laboratory workflow processes for a broad range of clinical samples”



 
Comment

No Very




Captcha Image

Sign up for updates